# Who does Biogen Inc. pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/biogen · Facet: suppliers · Updated: 2026-09-23T09:44:39.939106+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Biogen Inc.'s confirmed suppliers/cost counterparties include Eisai, Fujifilm Holdings plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 3 cost edges, backed by 3 dated sources, 1 of them primary filings (as of 2026-09-23).

### Stoke Therapeutics (high)
- metric: Amount $165M · FY2025 · Upfront payment at closing of the zorevunersen collaboration and license agreement
- note: Biogen paid Stoke $165 million upfront for a collaboration covering co-development and ex-North American commercialization rights to zorevunersen for Dravet syndrome.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-06) https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm: "Upfront payment of $165.0 million made to Stoke in connection with the closing of our collaboration and license agreement."

### Alcyone Therapeutics (high)
- metric: Amount $85M · FY2025 · Total consideration for the Alcyone Therapeutics acquisition
- note: Biogen acquired Alcyone Therapeutics in November 2025 to secure ThecaFlex DRx, an intrathecal drug-delivery device. Consideration was approximately $85 million as of year-end 2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-06) https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm: "In November 2025 we completed the acquisition of all issued shares of Alcyone; total consideration was approximately $85.0 million."
- [confirms] Intro-act (EN, research, published 2025-10-09) https://www.intro-act.com/uploads/allnewsletter/2025100912360735504670.pdf: "Biogen has agreed to acquire Alcyone Therapeutics for $85 million upfront, with additional payments contingent on milestones."
- [confirms] Biogen Investor Relations (EN, ir, published 2025-09-18) https://investors.biogen.com/node/29651: "Biogen has agreed to acquire Alcyone Therapeutics for an upfront cash payment of $85M plus certain milestones."

### 에자이 (high)  → /eisai.md
- metric: Market share 50 PERCENT · 협업 계약기간 · Biogen share of LEQEMBI research, development, sales and marketing costs
- note: Biogen shares LEQEMBI research, development, sales and marketing costs equally with Eisai. Eisai also has a supply agreement for Biogen to manufacture LEQEMBI drug substance and drug product through 2031.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-06) https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm: "All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai."

### 후지필름홀딩스 (mid)  → /fujifilm-holdings.md
- note: When Biogen sold its Hillerød site to the Fujifilm group, it entered manufacturing-services agreements for commercial biologics including TYSABRI. The manufacturing consideration was not disclosed.
- [confirms] Yonhap News Agency (KO, news, published 2019-03-13) https://www.yna.co.kr/view/AKR20190312160400017: "Biogen sold the Hillerød facility to Fujifilm for $890 million, and the existing manufacturing contracts transferred to Fujifilm."
- [confirms] Biogen Investor Relations (EN, ir, published 2019-03-12) https://investors.biogen.com/node/20891: "Fujifilm will use the Hillerød site to produce commercial products for Biogen, such as TYSABRI."

Reverse side: https://valuechain.wiki/biogen/customers.md · Ripple: https://valuechain.wiki/biogen/ripple.md

---
Full node: https://valuechain.wiki/biogen.md · JSON: https://valuechain.wiki/biogen.json